ES 028
Alternative Names: ES-028Latest Information Update: 28 Aug 2025
At a glance
- Originator Elpiscience Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action SIRPA protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for preclinical development in Solid-tumours in China
- 29 Dec 2021 Elpiscience Biopharmaceuticals plans global clinical trials in Solid tumours (for Monotherapy and Combination therapy) (Elpiscience Biopharmaceuticals pipeline, December 2021)
- 30 Jul 2021 ESC 028 is available for licensing as of 30 Jul 2021. (Elpiscience Biopharmaceuticals, July 2021)